What is the main business of Anpharm Przedsiębiorstwo Farmaceutyczne?

The main business activity of Anpharm Przedsiębiorstwo Farmaceutyczne focuses on manufacture of pharmaceutical preparations.

When was the company founded?

The company was registered in the Polish National Court Register (KRS) on July 9, 2001.

Where is the headquarters located?

The headquarters is located at: Annopol 6B, 03-236 Warszawa.

Who is on the management board?

The management board consists of: Jérôme Charles Schneeberger (Member of the Management Board) and Philippe Dartiguelongue (Member of the Management Board).

What is the share capital?

The share capital of the company is PLN 7,892,148 (approx. $2.1 million).

What period do the latest financial data cover?

The latest available financial statement covers the period from October 1, 2021 to September 30, 2022.

What revenue was generated?

The company reported a revenue of $111,469,394 in 2022, which is an increase of 0.7% compared to 2021.

Is the company profitable?

Yes, the company recorded a net profit of $6,051,493 in 2022, meaning the company decreased its profit by 17.7%.

Which cost dominates operating expenses?

The largest operating cost category falls under materials and energy. This category amounted to $97,678,167 in 2022, representing 95% of all operating expenses.

Anpharm Przedsiębiorstwo FarmaceutyczneS.A.

Manufacture of pharmaceutical preparations

KRS: NIP: REGON:

Overview

Status

Active

Registry date

2001-07-09

Share capital

7 892 148,00 PLN

Activity description

Anpharm Przedsiębiorstwo Farmaceutyczne is a manufacturing facility of the Servier Group in Poland that produces pharmaceuticals. It adheres to GMP quality standards and exports its products to 30 countries, focusing on therapeutic areas such as cardiometabolism, oncology, and neurology.

Registered address

Annopol 6B, 03-236 Warszawa, Poland

Website

anpharm.pl

Phone

Social media

Electronic delivery address

AE:PL-73816-73944-AWEHT-26

Financials

Revenue history (in m)

Data and insights are generated automatically based on financial statements and may contain errors. This analysis is for informational purposes only and does not constitute an official assessment of the company's credibility or business advice.

Statistics

How the company ranks by revenue within its industry, region and across Poland in 2025.

Results vs industry

Revenue

This companyUSD 160.17mMedianUSD 782.27kAverageUSD 24.03m

Net profit

This companyUSD 6.71mMedianUSD 7.91kAverageUSD 2.59m

Operating costs

This companyUSD 149.95mMedianUSD 723.93kAverageUSD 19.92m

Assets

This companyUSD 105.99mMedianUSD 800.34kAverageUSD 29.11m

Industry

Bank accounts

Registered as a VAT taxpayer on 1995-12-01. Active

Société Générale Oddział w Polsce
89 1840 0007 2211 2410 0810 1619
Société Générale Oddział w Polsce
35 1840 0007 2211 2410 0819 2510

Debt

No entries in the National Debtors Register (KRZ). No proceedings in KRZ

Public aid

No public aid cases recorded in the last 10 years.

Tenders

No recorded participation in tenders.

Trademarks

Anpharm Przedsiębiorstwo Farmaceutyczne currently holds no active trademarks with the Polish Patent Office. 11 marks have expired or were not registered. The first mark was filed in 1995.

Mark	Number	Classes	Status	Protected until
glimebet(word)	Z.282849	5	Expired	–
ANPHARM	Z.274854	5	Expired	–
CORAMIL(word)	Z.261434	5	Expired	–
RAMIVAC(word)	Z.261432	5	Expired	–
URIBICALAN(word)	Z.257620	5	Not registered	–

Mark	Protected until
glimebet(word)	–
ANPHARM	–
CORAMIL(word)	–
RAMIVAC(word)	–
URIBICALAN(word)	–

Regulatory authorisations

Authority	Type	Status
BDO	BDO register entry	Active

Authorized Representatives

Marcin Wiesław Andziak – Attorney-in-fact (joint)

Jérôme Charles Schneeberger – Management Board Member

Philippe Dartiguelongue – Management Board Member

Grzegorz Trębiński – Attorney-in-fact (joint)

Manner of representation

Each member of the management board has the right to represent the company independently.

Supervisory board

Gilles Belloir – Supervisory Board Member

Hani Friedman – Supervisory Board Member

Stephane Mascarau – Supervisory Board Member

Beneficial owners

Person	Rights

Competitors

Name	Revenue	Website
Adamed PharmaS.A.	$541,927,181.76	adamed.com.pl
Aflofarm Farmacja Polskasp. z o.o.	$302,019,142.07	aflofarm.pl
Przedsiębiorstwo Produkcji Farmaceutycznej Hasco - LekS.A.	$119,621,017.71	hasco-lek.pl
Delpharm PoznańS.A.	$110,900,246.81	delpharm.com
Tarchomińskie Zakłady Farmaceutyczne PolfaS.A.	$102,988,448.02	polfa-tarchomin.com.pl
ICN Polfa RzeszówS.A.	$85,044,250.03	icnpolfa.pl
PolfarmexS.A.	$73,543,379.32	polfarmex.pl
BiotonS.A.	$72,911,351.08	bioton.com
Wrocławskie Zakłady Zielarskie HerbapolS.A.	$46,537,868.51	herbapol.pl
Phytopharm KlękaS.A.	$46,154,888.31	phytopharm.pl

Change history

Date	Event
2008-04-14	Share capital change (10,418,998.00 PLN → 7,892,148.00 PLN)
2002-03-18	Share capital change (7,561,998.00 PLN → 10,418,998.00 PLN)
2001-07-09	Entered in the register

FAQ

Last updated: 2026-04-01